Gastroenteritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 64 Published: July 29, 2022 Report Code: GDGMDHC22253IDB

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis – Drugs In Development, 2022, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 1, 3, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

* Global Markets Direct, is a research brand owned and operated by GlobalData.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).

– The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

  • Allakos Inc

    Beijing Kangleweishi Biotechnology Co Ltd

    Blue Lake Biotechnology Inc

    Bristol-Myers Squibb Co

    Chongqing Zhifei Biological Products Co Ltd

    Cocrystal Pharma Inc

    Kyowa Kirin Co Ltd

    Lanzhou Institute of Biological Products Co Ltd

    Medicago Inc

    Novo Medi Sciences Pvt Ltd

    RedHill Biopharma Ltd

    Regeneron Pharmaceuticals Inc

    Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastroenteritis – Overview

Gastroenteritis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gastroenteritis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastroenteritis – Companies Involved in Therapeutics Development

Allakos Inc

Beijing Kangleweishi Biotechnology Co Ltd

Blue Lake Biotechnology Inc

Bristol-Myers Squibb Co

Chongqing Zhifei Biological Products Co Ltd

Cocrystal Pharma Inc

Kyowa Kirin Co Ltd

Lanzhou Institute of Biological Products Co Ltd

Medicago Inc

Novo Medi Sciences Pvt Ltd

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Gastroenteritis – Drug Profiles

Antibodies for Gastroenteritis – Drug Profile

Product Description

Mechanism Of Action

benralizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

BLB-300 – Drug Profile

Product Description

Mechanism Of Action

cendakimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

dupilumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

HIL-214 – Drug Profile

Product Description

Mechanism Of Action

History of Events

lirentelimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

norovirus (polyvalent, virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

norovirus [strains GI.1 + GII.4] (bivalent) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

Norovirus Gastroenteritis – Drug Profile

Product Description

Mechanism Of Action

ondansetron hydrochloride CR – Drug Profile

Product Description

Mechanism Of Action

History of Events

rotavirus (virus like particle) vaccine – Drug Profile

Product Description

Mechanism Of Action

History of Events

rotavirus vaccine – Drug Profile

Product Description

Mechanism Of Action

rotavirus vaccine – Drug Profile

Product Description

Mechanism Of Action

Gastroenteritis – Dormant Projects

Gastroenteritis – Discontinued Products

Gastroenteritis – Product Development Milestones

Featured News & Press Releases

Mar 30, 2021: Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting

Nov 12, 2019: RedHill Biopharma announces publication of RHB-102 gastroenteritis phase 3 study results in JAMA

Oct 28, 2019: Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

Aug 05, 2019: Allakos announces AK002 met all prespecified primary and secondary endpoints in phase 2 randomized, double-blind, placebo-controlled study in patients with eosinophilic gastritis (EG) and/or eosinophilic gastroenteritis (EGE)

Oct 08, 2018: Allakos presents data from its eosinophilic gastrointestinal diseases program at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting

Mar 27, 2018: RedHill Biopharma Announces Two Oral Presentations on BEKINDA 24 mg for acute gastroenteritis at the SAEM 2018 Annual Meeting

Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Jun 14, 2017: RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis

Apr 19, 2017: RedHill Biopharma to Host R&D Day on BEKINDA for Acute Gastroenteritis and IBS-D

Apr 18, 2017: RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA

Feb 21, 2017: RedHill Biopharma Completes Treatment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis

Jan 12, 2017: RedHill Biopharma Provides Milestone Update on Bekinda

Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results

Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Gastroenteritis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Gastroenteritis – Pipeline by Allakos Inc, 2022

Gastroenteritis – Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022

Gastroenteritis – Pipeline by Blue Lake Biotechnology Inc, 2022

Gastroenteritis – Pipeline by Bristol-Myers Squibb Co, 2022

Gastroenteritis – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022

Gastroenteritis – Pipeline by Cocrystal Pharma Inc, 2022

Gastroenteritis – Pipeline by Kyowa Kirin Co Ltd, 2022

Gastroenteritis – Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022

Gastroenteritis – Pipeline by Medicago Inc, 2022

Gastroenteritis – Pipeline by Novo Medi Sciences Pvt Ltd, 2022

Gastroenteritis – Pipeline by RedHill Biopharma Ltd, 2022

Gastroenteritis – Pipeline by Regeneron Pharmaceuticals Inc, 2022

Gastroenteritis – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Gastroenteritis – Dormant Projects, 2022

Gastroenteritis – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Gastroenteritis, 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.